Fletcher J C, Richter G
Center for Biomedical Ethics, University of Virginia School of Medicine, Charlottesville, USA.
J Matern Fetal Med. 1996 Sep-Oct;5(5):232-44. doi: 10.1002/(SICI)1520-6661(199609/10)5:5<232::AID-MFM2>3.0.CO;2-I.
This paper examines some key ethical issues raised by trials of human gene therapy in the perinatal period--i.e., in infants, young children, and the human fetus. It describes five resources in ethics for researchers' considerations prior to such trials: (1) the history of ethical debate about gene therapy, (2) a literature on the relevance of major ethical principles for clinical research, (3) a body of widely accepted norms and practices, (4) knowledge of paradigm cases, and (5) researchers' own professional integrity. The paper also examines ethical concerns that must be met prior to any trial: benefits to and safety of subjects, informed assent of children and informed parental permission, informed consent of pregnant women in fetal gene therapy, protection of privacy, and concerns about fairness in the selection of subjects. The paper criticizes the position that cases of fetal gene therapy should be restricted only to those where the pregnant woman has explicitly refused abortion. Additional topics include concerns about genetic enhancement and germ-line gene therapy.
本文探讨了围产期(即婴儿、幼儿和人类胎儿)人类基因治疗试验所引发的一些关键伦理问题。它描述了研究人员在进行此类试验之前进行伦理考量的五种资源:(1)关于基因治疗的伦理辩论历史,(2)关于主要伦理原则与临床研究相关性的文献,(3)一系列广泛接受的规范和实践,(4)范式案例知识,以及(5)研究人员自身的职业操守。本文还探讨了在任何试验之前必须满足的伦理考量:受试者的受益和安全、儿童的知情同意和父母的知情许可、胎儿基因治疗中孕妇的知情同意、隐私保护以及受试者选择中的公平性问题。本文批评了那种认为胎儿基因治疗案例应仅局限于孕妇明确拒绝堕胎的情况的观点。其他主题包括对基因增强和生殖系基因治疗的担忧。